Showing results (11-20 of 32) with videos related to

Sort By:
Pageof 4
Prostaglandins, Leukotrienes, and Medicine|January 1, 1984
Specific binding of 15 HETE to lymphocytes. Effects on the fluidity of plasmatic membranesS Mexmain, N Gualde, J C Aldigier, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|September 9, 2000
Deregulated platelet-activating factor levels and acetylhydrolase activity in patients with idiopathic IgA nephropathyY Denizot, C Aupetit, F Bridoux, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|October 21, 1999
Whole blood production of monocytic cytokines (IL-1beta, IL-6, TNF-alpha, sIL-6R, IL-1Ra) in haemodialysed patientsY Le Meur, V Lorgeot, J C Aldigier, et al.
Prostaglandins, Leukotrienes, and Medicine|January 1, 1984
Immunosuppression induced in vivo by 15 hydroxyeicosatetraenoic acid (15 HETE)J C Aldigier, N Gualde, S Mexmain, et al.
The Journal of Cardiovascular Surgery|February 14, 1998
M-CSF serous rate evolution during post-transplantation days in a heterotopic heart graft model miceE Cornu, P Lacroix, P Virot, et al.
Kidney International|September 6, 2000
Alleles of the alpha1 immunoglobulin gene 3' enhancer control evolution of IgA nephropathy toward renal failureC Aupetit, M Drouet, E Pinaud, et al.
Prostaglandins, Leukotrienes, and Essential Fatty Acids|October 1, 1992
NZB/NZW F1 mouse nephritis and immune response are not changed by treatment with a 15-lipoxygenase derivativeJ C Aldigier, J Cook, S Delebassée, et al.
Clinical Nephrology|May 15, 2002
Analysis of three genetic markers in IgA nephropathy patients from a single regionM Drouet, C Aupetit, Y Denizot, et al.
Immunology|May 31, 2001
Polymorphism of the human alpha1 immunoglobulin gene 3' enhancer hs1,2 and its relation to gene expressionY Denizot, E Pinaud, C Aupetit, et al.
Journal of Hypertension|March 4, 2000
Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal DiseaseL M Ruilope, J C Aldigier, C Ponticelli, et al.
Pageof 4